Magenta Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Magenta Therapeutics, Inc. - overview
Established
2015
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Magenta Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapies that harness the power of stem cells to address serious diseases. Their approach emphasizes cellular therapeutics aimed at transforming patient outcomes. Founded in 2015, Magenta Therapeutics, Inc.
is dedicated to pioneering stem cell-based therapies. Headquartered in Cambridge, US, the company has successfully raised funding totaling USD 86. 40 mn across multiple rounds, with its latest round, PIPE, occurring in June 2020, featuring investors like Deep Track Capital and OrbiMed Advisors. Jason Gardner serves as the CEO, and the company has made significant strides, including raising USD 100 million in an IPO in June 2018.
Magenta Therapeutics specializes in developing advanced biotechnological solutions, primarily focusing on stem cell therapies aimed at treating various serious diseases. The company's core products are designed to promote efficient patient care through innovative treatments that enhance the healing process. Their offerings have gained traction among healthcare providers and researchers seeking effective solutions in transplant medicine. Magenta Therapeutics markets its therapies globally, with a strong emphasis on collaboration with medical institutions to improve patient outcomes.
For the most recent fiscal year 2023, Magenta Therapeutics reported revenue of USD 2. 83 mn and an EBITDA of USD -44. 97 mn. The company employs a subscription-based model for its services, which enables healthcare partners to access their innovative therapies while fostering direct relationships with end-users.
Magenta Therapeutics plans to expand its product lineup with new stem cell therapies that are currently in development, aiming for launches in the upcoming years. The company is also targeting expansion into European and Asian markets by 2025 to increase its global footprint. The recent funding of USD 86. 40 mn will support these initiatives, particularly in advancing clinical trials and product development, enhancing the company's capability to deliver innovative solutions in regenerative medicine.
Current Investors
Atlas Venture, Access Industries, Third Rock Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.magentatx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Magenta Therapeutics, Inc. - timeline of key events
Magenta Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (59,088,000) | (81,126,000) | (76,545,000) | (71,964,000) | (78,769,000) | - | - | - |
| Operating Income (USD) | (59,963,000) | (82,969,000) | (78,702,000) | (74,692,000) | (80,902,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (57,515,000) | (76,769,000) | (74,936,000) | (71,136,000) | (76,462,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
Magenta Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.